California 2023-2024 Regular Session

California Senate Bill SB339

Introduced
2/7/23  
Refer
2/15/23  
Introduced
2/7/23  
Refer
3/14/23  
Refer
2/15/23  
Report Pass
4/11/23  
Refer
3/14/23  
Report Pass
4/11/23  
Refer
4/11/23  
Report Pass
4/27/23  
Report Pass
4/27/23  
Refer
4/27/23  
Report Pass
5/18/23  
Report Pass
5/18/23  
Engrossed
5/22/23  
Refer
5/26/23  
Engrossed
5/22/23  
Report Pass
6/28/23  
Refer
5/26/23  
Refer
6/29/23  
Report Pass
6/28/23  
Refer
6/29/23  
Report Pass
7/11/23  
Report Pass
7/11/23  
Refer
7/11/23  
Report Pass
9/1/23  
Report Pass
9/1/23  
Report Pass
9/1/23  
Enrolled
1/22/24  
Enrolled
1/22/24  
Enrolled
1/22/24  
Chaptered
2/6/24  
Chaptered
2/6/24  
Passed
2/6/24  

Caption

HIV preexposure prophylaxis and postexposure prophylaxis.

Impact

If SB339 is enacted, it could have significant implications for state healthcare laws by streamlining the process for obtaining PrEP and PEP medications through licensed pharmacists. Specifically, the bill mandates that health care service plans and insurers cover these medications when provided by pharmacists, thus expanding the scope of pharmacist services under Medi-Cal. This move seeks to reinforce the state's commitment to improving public health and reducing HIV transmission rates.

Summary

Senate Bill 339, introduced by Senator Wiener, aims to enhance the availability of HIV preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) in California. The bill proposes several amendments to existing pharmacy and health care regulations, enabling pharmacists to furnish up to a 90-day supply of PrEP and PEP, rather than the previous maximum of 60 days. This change creates better accessibility for individuals seeking preventive measures against HIV, thereby addressing a critical public health need.

Sentiment

The sentiment surrounding SB339 is largely positive amongst public health advocates and providers, who see the bill as a vital step toward enhancing access to essential HIV prevention services. However, there is also a sense of urgency among health officials to ensure that the implementation of these new regulations is efficient and equitable. Some concerns have been noted regarding the readiness of pharmacists to handle the expanded responsibilities safely and effectively, necessitating adequate training and resources.

Contention

Notable points of contention have emerged during discussions of SB339 related to the broader implications of pharmacist autonomy in prescribing and dispensing medications beyond traditional roles. Critics have raised concerns about potential overreach and the adequacy of training that pharmacists would receive, emphasizing the need for robust guidance from health care authorities. Additionally, the requirement for health insurers to cover these medications could face pushback, particularly regarding the cost and feasibility of implementation.

Companion Bills

No companion bills found.

Similar Bills

CA SB159

HIV: preexposure and postexposure prophylaxis.

CA SB427

Health care coverage: antiretroviral drugs, drug devices, and drug products.

CA AB554

Health care coverage: antiretroviral drugs, drug devices, and drug products.

CA AB602

Public postsecondary education: student behavior: drug and alcohol use: rehabilitation programs.